98%
921
2 minutes
20
Background: Infection with Trichomonas vaginalis (TV) is the most prevalent curable sexually transmitted infection (STI) globally and is associated with prelabour rupture of membranes, preterm delivery, and low birthweight. Point-of-care (POC) testing for TV during pregnancy may facilitate rapid antenatal case detection and treatment. This study, part of the World Health Organization's global ProSPeRo study, aimed to evaluate the performance of OSOM® Trichomonas Rapid Test, an antigen-based POC test, against a reference nucleic acid amplification test (NAAT) among pregnant women in Zambia. We also assessed the operational characteristics and patient acceptability of the POC test, within the context of WHO's target product profiles for STI POC tests.
Methods: We enrolled pregnant women attending four health centres in Nchelenge, Zambia, for antenatal care between 15 February and 26 May 2023. Vaginal swabs for the TV POC test and a reference NAAT (Aptima® Trichomonas vaginalis assay) were obtained. POC test results were read independently by two study staff members. Study staff filled a questionnaire on the operational characteristics of the POC test, and participants were asked about their willingness to wait for results.
Results: Paired POC and reference test samples were collected from 1,015 participants. Overall, 23.0% (233/1015) tested positive for TV by NAAT, and 15.3% (155/1015) tested positive by the POC test, with three inconclusive results. The overall sensitivity and specificity of the POC test were 66.4% (95% confidence intervals [CI] 57.7-74.1%) and 99.6% (95% CI: 98.8-99.9%), respectively. Sensitivity was higher among those with TV-associated symptoms compared to those without (83.6% versus 60.4%, relative ratio 1.39, 95% CI 1.14-1.68). Inter-rater agreement was 99.7% (Cohen's Kappa 0.989). The study staff (n = 14) found the test easy to use and interpret, with most staff (12/14) reporting results were available within 25 min.
Conclusion: Overall, the TV POC test showed lower sensitivity than WHO's 85% target, but exceeded the 99% specificity target. Among symptomatic pregnant women, sensitivity nearly reached the WHO target. The assay was user-friendly, required minimal training, and delivered results quickly. Further studies are needed to determine the optimal antenatal settings for this technology.
Trial Registration: PACTR202302766902029.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905427 | PMC |
http://dx.doi.org/10.1186/s12879-025-10698-9 | DOI Listing |
BMC Health Serv Res
September 2025
Rakai Health Sciences Program, P.O. Box 279, Kalisizo, Uganda.
Background: Hemoglobin estimation (Hb) is the most requested hematology test, especially among pregnant/postnatal women and people living with HIV (PLHIV). In Uganda, several point-of-care (POC) Hb testing devices are currently used and performance may be affected by multiple factors. This study evaluated the diagnostic and analytic performance of four Hb POC devices.
View Article and Find Full Text PDFJACC Case Rep
September 2025
Atrium Health Navicent, Macon, Georgia, USA.
Background: Pulmonary hypertension (PH) is frequently underdiagnosed due to limitations of transthoracic echocardiography, particularly when tricuspid regurgitant velocity (TRV) is unmeasurable. CorVista PH (point-of-care test for pulmonary hypertension [POC-PH]) is a novel, Food and Drug Administration-cleared point-of-care diagnostic with 82% sensitivity and 92% specificity for identifying mean pulmonary artery pressure elevation.
Summary: We present a patient who underwent multiple transthoracic echocardiograms negative for PH.
J Clin Psychiatry
September 2025
Therapeutic Area Mental Health, Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany.
To assess proof-of-concept (PoC) for efficacy, tolerability, and safety of TRPC4/5 inhibitor BI 1358894 vs placebo in patients with major depressive disorder (MDD) with inadequate response to ongoing antidepressants. In this phase 2, multicenter, randomized, double-blind, dose-finding trial (December 2020-February 2024), patients with MDD (per ) and current depressive episode of ≥8 weeks and ≤24 months were randomized (3.5:1:1:1:2:2) to receive placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) or quetiapine 150-300 mg orally, once daily for 6 weeks.
View Article and Find Full Text PDFJMIR Res Protoc
September 2025
Scientific Direction, Istituto Nazionale di Riposo e Cura per Anziani, Ancona, Italy.
Background: Dementia is challenging society in terms of the quality of life, the costs of health care systems, and caregivers' burden. Dementia is often preceded by a status of mild cognitive impairment (MCI), during which a healthy lifestyle and cognitive therapy seem to be effective in counteracting the decline.
Objective: The engAGE (Managing Cognitive Decline Through Theatre Therapy, Artificial Intelligence, and Social Robot-Driven Interventions) project aimed to build a technological platform to counteract cognitive decline in older adults with MCI through both cognitive therapy and lifestyle management.
Background And Aims: Glycated Hemoglobin (HbA1c) is crucial for diagnosing and monitoring diabetes. However, current tests are complex, invasive, costly, and often met with low compliance. This study aimed to find whether simple clinical, noninvasive measures of the ocular accommodation function may predict the glycated hemoglobin results in type-1 diabetes mellitus.
View Article and Find Full Text PDF